ReviewObstetrical & gynecological survey2019
Cardiometabolic Risk Factors and Benign Gynecologic Disorders.
Review in Obstetrical & gynecological survey, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Meta-Analysis of 16S rRNA Sequencing Reveals Altered Fecal but Not Vaginal Microbial Composition and Function in Women with Endometriosis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Uterine fibroids and hypertensive disorders of pregnancy: Persistence of risk regardless of myomectomy or fibroid location.Pregnancy hypertension · 2026Article
- Emulating a target trial of surgical removal of uterine fibroids on atherosclerotic cardiovascular disease.Fertility and sterility · 2026Article
- Angiotensin II drives proliferation and extracellular matrix deposition in human uterine fibroid cells in vitro.F&S science · 2026Article
- The Invisible Burden: Examining the Impact of Exposure Misclassification in Epidemiologic Analyses of Uterine Fibroids.Paediatric and perinatal epidemiology · 2026Article
- Association Between Uterine Fibroids and Risk of Atherosclerotic Cardiovascular Disease.Journal of the American Heart Association · 2026Article
- Integrating reproductive and metabolic factors for uterine fibroid risk assessment: a two-center machine learning study with SHAP interpretability.Frontiers in oncology · 2026Article
- The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications-A Narrative Review.Biomedicines · 2025Review
- Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition, and disease.Frontiers in global women's health · 2025Review
- Common Beverage Consumption and Benign Gynecological Conditions.Beverages (Basel, Switzerland) · 2024Article
- Association between uterine leiomyoma and fragmented QRS waves: a prospective case-control study.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Article
- Oxidative Stress and Antioxidants in Uterine Fibroids: Pathophysiology and Clinical Implications.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- Adipocyte coculture induces a pro-inflammatory, fibrotic, angiogenic, and proliferative microenvironment in uterine leiomyoma cells.Biochimica et biophysica acta. Molecular basis of disease · 2023Article
- Leptin induces leiomyoma cell proliferation and extracellular matrix deposition via JAK2/STAT3 and MAPK/ERK pathways.F&S science · 2022Article
- Endometriosis promotes atherosclerosis in a murine model.American journal of obstetrics and gynecology · 2022Article
- Obesity and risk of female reproductive conditions: A Mendelian randomisation study.PLoS medicine · 2022Article
- The Future of Uterine Fibroid Management: a More Preventive and Personalized Paradigm.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
importanceWhile it has long been known that polycystic ovarian syndrome is associated with cardiometabolic risk factors (CMRFs), there is emerging evidence that other benign gynecologic conditions, such as uterine leiomyomas, endometriosis, and even hysterectomy without oophorectomy, can be associated with CMRFs. Understanding the evidence and mechanisms of these associations can lead to novel preventive and therapeutic interventions.
objectiveThis article discusses the evidence and the potential mechanisms mediating the association between CMRFs and benign gynecologic disorders. EVIDENCE ACQUISITION: We reviewed PubMed, EMBASE, Scopus, and Google Scholar databases to obtain plausible clinical and biological evidence, including hormonal, immunologic, inflammatory, growth factor-related, genetic, epigenetic, atherogenic, vitamin D-related, and dietary factors.
resultsCardiometabolic risk factors appear to contribute to uterine leiomyoma pathogenesis. For example, obesity can modulate leiomyomatous cellular proliferation and extracellular matrix deposition through hyperestrogenic states, chronic inflammation, insulin resistance, and adipokines. On the other hand, endometriosis has been shown to induce systemic inflammation, thereby increasing cardiometabolic risks, for example, through inducing atherosclerotic changes. CONCLUSION AND RELEVANCE: Clinical implications of these associations are 2-fold. First, screening and early modification of CMRFs can be part of a preventive strategy for uterine leiomyomas and hysterectomy. Second, patients diagnosed with uterine leiomyomas or endometriosis can be screened and closely followed for CMRFs and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.